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Abstract 
 
Although it has been known for more than twenty years that an aberrant conformation of 
the prion protein (PrP) is the causative agent in prion diseases, the role of PrP in normal 
biology is undetermined. Numerous studies have suggested a protective function for PrP, 
including protection from ischemic and excitotoxic lesions and several apoptotic insults. On the 
other hand, many observations have suggested the contrary, linking changes in PrP 
localization or domain structure—independent of infectious prion conformation—to severe 
neuronal damage. Surprisingly, a recent report suggests that PrP is a receptor for toxic 
oligomeric species of a-β, a pathogenic fragment of the amyloid precursor protein, and likely 
contributes to disease pathogenesis of Alzheimer’s disease. We sought to access the role of 
PrP in diverse neurological disorders. First, we confirmed that PrP confers protection against 
ischemic damage using an acute stroke model, a well characterized association. After 
ischemic insult, PrP knockouts had dramatically increased infarct volumes and decreased 
behavioral performance compared to controls. To examine the potential of PrP’s 
neuroprotective or neurotoxic properties in the context of other pathologies, we deleted PrP 
from several transgenic models of neurodegenerative disease. Deletion of PrP did not 
substantially alter the disease phenotypes of mouse models of Parkinson’s disease or 
tauopathy. Deletion of PrP in one of two Huntington’s disease models tested, R6/2, modestly 
slowed motor deterioration as measured on an accelerating rotarod but otherwise did not alter 
other major features of the disease. Finally, transgenic overexpression of PrP did not 
exacerbate the Huntington’s motor phenotype. These results suggest that PrP has a context-
dependent neuroprotective function and does not broadly contribute to the disease models 
tested herein.  
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Introduction 
 
Neurodegenerative disorders are among the most common affliction of the aged 
population; millions suffer worldwide from Alzheimer’s disease (AD), Parkinson’s disease (PD), 
amyotrophic lateral sclerosis, Huntington’s disease (HD), and several other more rare 
conditions, such as prion disease.1,2 Neurodegenerative diseases of aging typically manifest 
as clinically separable disorders in which certain regions of the brain deteriorate. One 
commonality for most common neurodegenerative diseases is the presence of specific 
misfolded protein(s).3 PD is characterized by the aggregation of α-synuclein in Lewy bodies 
within neuronal soma, and neuron loss in the substantia nigra of the midbrain and other areas 
of the brain.4 An entire class of diseases, the tauopathies (TP), demonstrate an accumulation 
of the microtubule associated protein, tau.5 HD is a dominantly heritable, neurodegenerative 
disorder caused by a polyglutamine repeat expansion in the first exon of the huntingtin protein, 
resulting in neuronal loss in the striatum and cerebral cortex.6 Developing therapies for these 
diseases is hampered by our poor understanding of the precise mechanism(s) of how 
misfolding of these proteins causes dysfunction and death and which misfolded species to 
target.  
Prion diseases are an intensively studied class of neurodegenerative diseases, 
affecting a range of mammalian hosts, transmittable between species.7 Prion diseases also 
occur in sporadic and inherited forms. The prion protein (PrP) is an N-linked glycoprotein 
tethered to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor.8 The prion 
hypothesis posits that infectious prion disease arises when the normal host isoform of PrP, 
termed PrPC, is converted into a misfolded conformer, PrPSc which is capable of further 
templating this process.8 Consistent with this notion, the higher the levels of PrP, the more 
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rapidly prion disease progresses in transgenic mice overexpressing PrP.9 Advances into the 
understanding of infectious prion disease have shown that PrP expression in neurons is a 
requirement for neurotoxicity;10 moreover, PrP must retain its GPI anchor11 to damage neural 
tissue during prion disease. We have recently implicated heat shock factor 1 as a mediator of 
protection against prion disease in vivo12 and other research suggests that inflammation is a 
major contributor to prion pathogenesis.13 Beyond these observations, the molecular 
mechanism(s) of prion-induced neuronal toxicity remain unresolved.14-17  
A multitude of biological functions have been attributed to PrPC, with several lines of 
evidence suggesting a neuroprotective function.15,18-21 Studies by several groups have 
demonstrated that PrP knockout mice (KO) are more susceptible to ischemic damage22-24 and 
excitotoxic lesion by dampening activity of an NMDA receptor subtype.14,25 In addition, PrP can 
protect against toxicity associated with ectopic expression of its closest paralog, Doppel, as 
well as truncated PrP mutants.26-29 In cultured cells, PrPC expression protects against 
apoptosis induced by overexpression of pro-apoptotic Bax30 and against oxidative stress.31,32 
Thus, there is ample evidence that PrPC helps maintain cellular integrity during stressful 
conditions. However, this must be reconciled with the fact that PrP is a disease-causing agent 
when it misfolds during prion disease. Also, there is conflicting evidence suggesting that PrPC 
is not neuroprotective and that it sensitizes cells to toxicity and death. Agents that cause ER 
stress show enhanced toxicity in cells expressing PrP.32 Also, when proteasome activity is 
compromised neurons expressing higher levels of PrP are more susceptible to apoptosis.33 
Mislocalizing PrPC to the cytosol causes neurotoxicity in vitro and in vivo,33-34 possibly by 
inhibiting the activity of the proteasome.34 To further complicate matters, several transgenic 
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lines of mice overexpressing wild-type (WT) PrP develop neurologic disease,35,36 suggesting 
that too much PrPC can wreak havoc on tissues.  
A growing number of studies suggest indirect and direct influences of PrP on other 
neurodegenerative diseases. Several studies have implicated PrP in the pathogenesis of AD. 
One report reveals that PrP is a negative regulator of β-secretase activity, which leads to the 
production of a toxic fragment of the amyloid precursor protein, a-β.37 The straightforward 
interpretation of this data is that PrP would be a protective factor against AD. However, 
Schwarze-Eicker and colleagues report that transgenic overexpression of PrP enhances 
amyloid plaque formation in a mouse model of AD.38 Another striking finding is that PrP 
behaves as a cellular receptor for a-β oligomeric species and thus appears to have a role in 
promoting neuronal dysfunction during AD.39 Further experiments will be required to settle this 
question. Crosstalk between PrP and other neurodegenerative disease causing proteins is not 
limited to AD, as another report has suggested that PrP protects against polyglutamine 
aggregate toxicity.40 Tau, another pathological hallmark of AD, was recently implicated as an 
interaction partner of PrP in in vitro assays,41 raising a possible connection between TPs and 
PrP. Indeed, the deposition of neurofibrillary tangles of hyperphosphorylated tau protein, a 
pathological hallmark of AD and TP, has been noted in many cases of prion disease linked to 
mutations in PrP or sporadic Creutzfeldt Jacob disease (CJD).42,43 There is additional clinical 
overlap among neurodegenerative diseases that may involve PrP. Some cases of diagnosed 
HD are actually caused by a mutation in the gene encoding PrP (PRNP) rather than any 
alteration to the huntingtin gene.44,45 PRNP mutations can also be associated with some PD-
like symptoms and neuropathology46 and some demonstrate similarities to the tauopathies.47  
Collinge and colleagues described a kindred segregating pre-senile dementia, AD, HD, PD, 
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Pick's disease, as well as prion disease (Gerstmann-Straussler-Scheinker syndrome and 
CJD). Remarkably, it was found that this family had a mutation within the PRNP coding 
sequence,48 suggesting that mutant PrP could give rise to many different neurodegenerative 
disease symptomologies. 
We conducted experiments to address two questions: 1) does the neuroprotective 
function of PrP extend to a broad spectrum of neurodegenerative pathologies? 2) Or 
alternatively, does PrP play a contributing role to neurodegenerative disease pathology? To 
address these questions we crossed transgenic models of PD, TP, and HD (listed in Table I) 
into a PrP KO background and followed the disease progression relative to that of control 
mice. We began by confirming the neuroprotective role of PrP in an acute ischemia model, 
where PrP deletion causes significantly higher levels of damage as measured by lesion 
volume and behavior. However, PrP deletion did not have a substantial impact on any of the 
neurodegenerative disease models tested, suggesting that – at least in so far as they are 
modeled in the mouse – PrP is not a major contributing factor to the disease processes we 
examined. 
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Materials and Methods 
 
Mouse strains, genotyping, and breeding strategy: 
 
All experiments using mice were approved by the institutional animal care and use 
committee. PrP KO mice49 were obtained from Rick Race (Rocky Mountain Laboratories 
NIAID/NIH) on a mixed genetic background comprised of 129/Ola, C57Bl/10, and C57Bl/6 (2 
backcrosses to C57Bl/6 were performed in our facility). The “JNPL3” tau mutant (P301L)50 on a 
mixed genetic background comprised of C57Bl/6, DBA/2, and Swiss Webster was obtained 
from Taconic Farms.  The PD mouse51 on a mixed genetic background composed of C57Bl/6 
and DBA/2 was kindly provided by Brad Hyman (Harvard Medical School). The “R6/2” HD 
mouse52 on a mixed genetic background comprised of CBA and C57BL/6 was obtained from 
Jackson Laboratories as ovarian transferred females. Trangenic mice overexpressing normal 
mouse Prnp (“Tga20”) was obtained from the European Mutant Mouse resource center and 
subsequently the PrP deletion alleles were bred out while the mice were backcrossed for at 
least six generations of C57Bl/6.53 A summary of all mice used in this paper is presented in 
Table I. 
DNA was extracted from tail clippings digested with proteinase K by isopropanol 
extraction. Amplification of transgenes was done according to published protocols for: PrP 
deletion or overexpression Tg,53 human α-synuclein,51 huntingtin fragment,52  and the following 
primers were used to amplify P301L Tau 5’TGAACCAGGATGGCTGAGC3’ and 
5’TTGTCATCGCTTCCAGTCC3’.  
The general breeding strategy used to generate experimental mice was to cross PrP 
KO mice to Tg mice expressing either human a-synuclein, mutant Tau, or polyglutamine 
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expanded HD.  The F1 progeny that were heterozygous for the PrP KO deletion allele and 
transgenic for the disease transgene were intercrossed, except for HD mice since Tg+ females 
do not breed. Thus, we crossed F1 males that were HD Tg+ PrP+/- to F1 female HD Tg-/- PrP 
+/- to obtain our experimental F2 animals. Expected Mendelian ratios of progeny were 
obtained from F1 intercrosses of PD and HD mice, but there was a conspicuous lack of PrP-/- 
mice in the TP crosses. We confirmed that this effect was independent of the mutant Tau 
transgene and was likely a polygenic interaction between PrP deletion and a combination of 
alleles in the mutant tau mouse genetic background, as PrP-/- mice were recovered in 
expected Mendelian ratios in crosses to all the inbred lines (C57Bl/6, DBA/2, and Swiss 
Webster) that comprise the mixed background of the mutant tau line (data not shown).   
Ischemia  
 
For ischemia studies male mice aged 2-3 months and weighing between 25 to 30 grams 
were used. The PrP KOs and controls were derived from the same breeding colony, which was 
at 10-11 generations of backcross of the PrP knockout allele onto a pure C57Bl/6J 
background. Transient middle cerebral middle artery occlusion was performed according to 
established protocols.54 Briefly, animals were anesthetized with 2% isoflurane and maintained 
on 1.5% isoflurane in 70% N2O and 30% O2 by a face mask. Cerebral infarcts were produce 
by 30 minutes of MCA occlusion followed by reperfusion and monitored as previously 
described.54 Cerebral infarct sizes were determined by image analysis (M4; Imaging Research) 
of vital dye (2,3,5-triphenyltetrazolium chloride) stained brain sections. Infarct volumes were 
calculated by integrating the infarct area in each brain section of the brain (shown in Figure 
1E). For neurological evaluation deficits were measured on a well established five-point 
neurological scale: 0, no neurologic deficit; 1, failure to extend the left forepaw fully; 2, circling 
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to the left; 3, falling or leaning over to the left; 4, no spontaneous walking and a depressed 
level of consciousness; or 5, dead.54 All animals tested had a score of 0 before undergoing 
fMCAO. 
Behavioral Analysis 
 
For motor performance, all mice were tested on an Ugo Basile accelerating rotorod, 
which was modified by placing a rubber bike inner tube on the on the rod to deter gripping. 
Mice were placed on the rotarod, and then the rotarod was accelerated 5 seconds after the 
mice were placed on the rod. The amount of time the mice remained on the rotarod was 
recorded. HD mice were weighed, rotarod tested, and clasp/escape tested twice weekly, 
beginning at 6 weeks of age (+/- 1 week). For reporting of rotarod data an average value from 
two trials was taken for HD mice. HD mice were also tested for the ‘clasping’ phenotype52 by 
suspending them from their tails with close proximity to the experimenter’s hand to allow for 
“escaping” which was also recorded. For clasping values a mouse was scored as positive if it 
clasped once or both times in twice-weekly trials.  PrP OE Tg HD mice were tested similarly 
and in addition they were video recorded once per week for home cage behavior analysis as 
described previously.55 PD mice were tested biweekly, beginning at 6 months old (+/- 2 
months)—data is shown as a monthly average for PD mice. Mutant Tau Tg mice were tested 
weekly, beginning at 10 weeks old (+/- 2 weeks) then tested bi-weekly once the mice reached 
6 months old until they were removed from the study due to paralysis. Rotarod data for TP 
mice is reported as group averages which were derived from averaging across each trial per 
month per mouse. For survival analysis, mice were sacrificed when they were moribund as 
determined in consultation with our veterinary staff. TP mice developed a severe hindlimb 
paresis and were sacrificed when they could not ambulate. HD mice were sacrificed when their 
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body condition reached 1-2; many mice were found dead or died when being handled from 
severe seizures. PD mice were sacrificed when they displayed low body condition. 
Immunohistochemistry 
 
For α-synuclein staining, coronal brain sections (40 μm) were cut on a Leica CM 1800 
cryostat.  Sections were washed in phosphate buffered saline (PBS, pH 7.4) and then 
incubated in 0.5% H2O2 in PBS for 15 min to block endogenous peroxidase.  After washing in 
PBS, sections are incubated in mouse IgG blocking reagent (M.O.M. kit, Vector Laboratories, 
Burlingame, CA, USA) for 1hour.  Sections are then incubated in the primary antibody, mouse 
anti-alpha synuclein (1:250, BD Biosciences, San Jose, CA, USA) at 4°C overnight.  Control 
sections are incubated with mouse IgG1 (1 μg/ml, Sigma).  Sections were washed in PBS and 
then incubated in the secondary antibody, biotinylated goat anti-mouse IgG (1:250, Millipore, 
Billerica, MA) for 2 hours.  The avidin-biotin complex method was used to detect the secondary 
antibody (ABC elite kit, Vector laboratories, Burlingame, CA) and the reaction product was 
visualized by 3,3’-diaminobenzidine tetrachloride (DAB, Sigma, St Louis, MO).  Sections were 
mounted on gelatin coated slides and air dried overnight.  Sections were then dehydrated and 
cleared with xylene, mounted with Eukit mounting medium (Calibrated Instruments, 
Hawthorne, NY), and examined under bright-field illumination with a Zeiss Axioskop 
microscope (Thornwood, NY). Digital images were captured by a Spot digital camera (Sterling 
Heights, MI). Neurofibrillary tangles of Tau were detected by immunostaining with a rabbit 
polyclonal anti-human Tau clone A 0024 (Dako) used at a 1:3000 dilution. Paraffin sections 
were dewaxed and then formic acid (90%) treated for five minutes prior to standard 
immunohistochemical staining as described above. Huntingtin immunostaining was performed 
similarly, using 10% normal horse serum in PBS for 1 hour to block non-specific antibody 
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binding and using goat anti-Huntingtin 1:100 (Santa Cruz Biotechnology, CA) at room 
temperature overnight.  Control sections were incubated with goat IgG at 2 μg/ml.  After rinses 
in PBS, the sections were incubated in biotinylated horse anti-goat antibody (1:200) (Vector 
ABC Elite, Burlingame, CA) for 2hr at room temperature. After several rinses in PBS, the 
sections were incubated for 2hr in avidin-biotin complex (Vector ABC Elite) in PBS. 
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Results 
 
PrP knockouts are more susceptible to ischemic injury 
 
 Reports by several groups have shown that PrP protects against ischemic damage.22-24 
We performed middle cerebral artery occlusions (MCAO) on C57Bl/6J PrP KO and congenic 
control mice for 30 minutes followed by a 22 hour reperfusion. Cerebral blood flow was 
measured in PrP WT and KO mice undergoing MCAO to confirm that both groups had nearly 
equivalent blockages of blood flow in the brain (Figure 1A). Similar to other reports, we 
observed that PrP KOs were dramatically sensitized to ischemic insult. We performed 
behavioral testing on PrP KOs and controls and noted that PrP KOs present higher clinical 
scores, indicative of more severe injury (the details of clinical assessment can be found in the 
Methods) both 2 and 24 hours after injury (Figure 1B). We next measured the infarct volume, 
the region of brain tissue that does not stain with vital dye, which was increased approximately 
2-fold in PrP KOs (Fig. 1C-D). An image of a control and PrP KO brain from MCAO treated 
mice is shown in Figure 1E. 
 
Deletion of PrP in an α-synuclein transgenic model of Parkinson’s disease 
 
Although no comprehensive model of PD existed at the onset of our studies, we chose 
to utilize a mouse model of PD which overexpresses human α-synuclein driven by a platelet-
derived growth factor-β promoter51 (Table I). This mouse was reported to mimic human 
pathologies seen in PD, such as loss of dopaminergic neurons, accumulation of α-synuclein 
aggregates, and motor dysfunction. Details of breeding and genetic backgrounds for all mouse 
lines are reported in the Methods section. Mice that were PD Tg+ and either wild-type (+/+), 
heterozygous (+/-), or null (-/-) for PrP were tested twice per month for motor performance by 
accelerating rotarod (Fig. 2A).56 We observed only a small decline in motor performance in PrP 
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+/+ α-synuclein Tg mice, suggesting that on the mixed genetic background of our study there 
was not a significant progressive rotarod deficit in α-synuclein Tg+ mice or that the repeated 
testing had a masking effect on this phenotype (Figure 2A). For example, the latency to fall off 
the accelerating rotarod was approximately 150 seconds at 5-8 months and even by 18 
months the latency to fall had only decreased to approximately 100 seconds. We noted a trend 
that PrP+/- and PrP-/- mice had worse motor performance from 12-18 months, but it reached 
statistical significance only at 14 months. Given the high variability within these groups and the 
fact that at 19-21 months all the groups behaved similarly, we concluded that if PrP deletion 
enhanced the disease phenotype, the effect was modest. Alternative tests with higher 
sensitivity have revealed phenotypes in other α-synuclein Tg mice.57  
 We also assessed survival in the α-synuclein Tg+ mice with different PrP gene dosage. 
There were no significant differences between α-synuclein Tg+ PrP +/+, +/-, or -/- in terms of 
survival (Figure 2B). Most of these mice lived an apparently normal lifespan, although we did 
not include sufficient α-synuclein Tg-/- controls to prove this point. Finally, we examined α-
synuclein staining in several α-synuclein Tg+ PrP+/+ and PrP-/- brains taken at 12-16 months 
of age. We did not detect any differences between groups in terms of α-synuclein deposition 
(Figure 2C-E). 
 
Deletion of PrP in a mutant tau transgenic model of tauopathy 
 
We utilized a transgenic model of TP that over-expresses mutant human Tau (P301L), 
which is associated with frontotemporal dementia associated with Parkinson’s disease in 
humans, driven by a modified murine PrP promoter.50 As previously described the P301L Tau 
Tg+ mice develop a severe motor phenotype, where their hind limbs eventually become 
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completely paralyzed and can be utilized as a general model of TP.50 Once signs of hind limb 
dysfunction were observed the mice typically had to be euthanized within 4 weeks. The motor 
performance of the populations of Tau Tg+ PrP+/+, +/-, and -/- mice showed a progressive 
decline in rotarod performance, but the kinetics of this decrease were indistinguishable 
between all groups of mice with different PrP levels (Fig. 3A). The decline in mean rotarod 
performance does not properly reflect the extreme paralysis of the Tau mutant mice because 
mice that developed paralysis were euthanized and removed from our rotarod study. 
We determined the survival of the P301L Tau Tg mice with different PrP gene 
dosages. There was a clear difference in survival between Tau Tg+ and Tau Tg-/- mice (both 
groups with WT levels of PrP) (data not shown). However, there were no statistically significant 
differences in the survival of any of the Tau Tg+ mice with 2, 1, or no copies of PrP (Figure 
3B). However, we also assessed tau pathology in several mice from this study. As expected, 
we observed a similar distribution of tau aggregation in brains from Tau Tg+ PrP+/+ and Tau 
Tg+ PrP-/- (Figure 3C-D). 
 
 
Deletion of PrP in polyglutamine expanded N-terminal huntingtin models of Huntington’s 
disease 
 
We also tested whether PrP deletion would alter the phenotype of a mouse model of 
HD. This commonly used HD model, termed “R6/2”, expresses the first exon of human 
huntingtin with an uninterrupted stretch of approximately 115-150 glutamines.52 These mice 
show severe motor impairments, dramatic weight loss, and many other phenotypes.52,55,58 
Motor impairment was assessed by testing these mice twice per week on an accelerating 
rotarod. Average values of these bi-weekly trials suggested that the motor impairment was 
slightly less severe in HD Tg+ PrP-/- mice (Fig. 4A). This subtle improvement persisted from 6 
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weeks until 12 weeks, but by 13 weeks and beyond there were no significant differences in 
rotarod performance between groups. We assessed survival in the HD Tg+ mice with differing 
PrP gene dosages. There were no significant differences in the survival of HD Tg+ PrP+/+, +/-, 
or -/- mice (Fig. 4B). We performed additional behavioral testing of HD mutant mice, including 
a tail suspension and escaping test; in this test a mouse is held suspended by its tail and 
healthy mice will typically “escape” onto the fingers of the experimenter and almost never clasp 
their fore and hind limbs. HD Tg+ mice progressively develop the clasping phenotype and lose 
their ability to escape, independent of PrP deletion (Fig. 4C-D). We measured body weights 
and observed a similar decline in body weight in HD Tg+ mice that was also independent of 
PrP levels (data not shown). Preliminary analysis of home cage behaviors of HD Tg+ PrP+/+ 
and HD Tg+ PrP-/- using video based behavior recognition technology55 also did not suggest 
any phenotypic differences between our experimental groups (data not shown). We also 
examined the brains of HD Tg+ PrP+/+ and HD Tg+ PrP-/- mice for huntingtin aggregation. 
Dramatic nuclear aggregates of huntingtin were observed by immunohistochemistry with no 
notable differences between HD Tg+ PrP+/+ and HD Tg+ PrP-/- (Fig. 4E-H). Thus, the HD Tg 
phenotype is mostly unaffected by PrP deletion with the exception of a modest improvement of 
rotarod performance in an early phase of disease. To further investigate the possible 
contribution of PrP to HD we also utilized a less severe HD model, termed “N171-82Q” (Table 
I).59 When deleted for PrP, the survival of this HD model was not altered (Fig. 4I), nor was 
motor performance, which was tested weekly from 6 to 19 weeks of age (data not shown). 
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Overexpression of PrP in polyglutamine expanded N-terminal huntingtin model of Huntington’s 
disease 
 
Since we observed a subtle amelioration of the decline in rotarod performance in HD 
Tg+ PrP-/- mice, we predicted that overexpression of PrP might enhance the well-described 
HD Tg phenotype. To test this prediction, we crossed the well characterized PrP 
overexpression “Tga20” transgenic mouse9 on a C57Bl/6 genetic background53 to the R6/2 HD 
Tg+ mice. With one copy of the Tga20 Prnp transgene (herein referred to as “PrP OE”) in a 
WT PrP background these mice express approximately 4-5 fold more PrP than WT mice.53 
Motor performance was assessed by rotarod and was indistinguishable between HD+ PrP 
OE+ mice and HD+ PrP OE- mice (Fig. 5A). We did not observe any effect on the survival of 
the HD Tg+ mice whether PrP was expressed at a WT level or overexpressed (Fig. 5B). The 
clasping and escaping phenotype was also similar between both groups of mice (Fig. 5C-D). 
Home cage behavior analysis, measuring hanging, rearing, jumping, eating, drinking, and 
distance traveled did not reveal any substantial differences between HD+ PrP OE+ and HD+ 
PrP OE- (data not shown, except for distance traveled, which is shown in Figure 5E). From 
these experiments we concluded that PrP overexpression does not affect the R6/2 HD 
phenotype.  
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Discussion 
 
In summary, we performed a series of long-term experiments designed to test whether 
PrP promotes or protects against disease in a panel of mouse models of neurodegenerative 
diseases. This study represents one of the most extensive cases where a single genetic 
mutation has been tested in combination with so many mammalian disease models. We 
observed that despite providing strong protection against ischemia, PrP was not a major 
modulator of the respective disease phenotypes of models of PD, TP, and HD except with the 
R6/2 HD Tg PrP-/- mice there was a modest delay in the impairment of motor performance 
relative to R6/2 HD Tg PrP+/+ mice. However, the other observed phenotypes of R6/2 mice, 
such as survival, were unaffected and transgenic overexpression of PrP did not affect the R6/2 
phenotype. In addition, we crossed the PrP KO to a different transgenic model of HD59 and did 
not observe any effect on the motor performance or survival dependent on PrP genotype. In 
the α-synuclein mouse model of PD there was a trend toward PrP+/+ mice performing better 
than PrP+/- and PrP-/- mice on the rotarod, but these animals failed to repeat the strong motor 
defects originally described in these transgenic mice.51 The lifespan of the α-synuclein 
transgenic mice (independent of PrP genotype) are quite long, on par with that of normal mice. 
Repeating this experiment with the next generation of α-synuclein transgenic mice57,60 may 
better address the potential role of PrP in contributing or protecting against α-synuclein toxicity.  
Our behavioral and neuropathological assays could only detect a major modification in 
any of the disease phenotypes tested, with the exception of the HD model. A closer 
examination of behavior and/or pathology may have revealed a subtle role for PrP in promoting 
or protecting against neurodegenerative diseases. While intercrossing of strains on pure 
genetic backgrounds may have facilitated detection of small differences between PrP-deleted 
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neurodegenerative disease models and controls, such backcrosses have their own limitations. 
Indeed, the R6/2 HD model is not viable on a pure background.52 Moreover, backcrossing to a 
pure background takes years and for reasons that are not clear, backcrossing 
neurodegenerative disease models onto pure backgrounds often does not increase the 
succinctness or robustness of their disease phenotypes (as with the P301L Tau transgenic 
[data not shown]). Thus, in our study we controlled for genetic background as well as was 
feasible with our breeding strategy by obtaining littermate controls from intercrossing Prnp +/- 
parents (one of which also carried the neurodegenerative disease transgene). 
 Our study touches upon a broader question of whether there is cross-talk among 
aggregation-prone proteins in neurodegenerative diseases, a notion well supported by the 
human disease literature (discussed in the Introduction). An elegant study in C. elegans 
demonstrated that under conditions of perturbed protein folding homeostasis, such as when a 
huntingtin fragment containing a polyglutamine expansion is expressed, a normally innocuous 
mutation became deleterious.61 Thus, misfolded proteins can act synergistically to harm cells. 
Whether these findings apply to human neurodegenerative diseases of aging is a pressing 
question and several findings suggest this question is worth further exploration, despite the 
failure of our study to reveal any contribution of wild-type PrP to other neurodegenerative 
diseases.  
Based on our mostly negative findings we cannot rule out the importance of PrP as a 
contributing or protective factor to human neurodegenerative diseases. By using the best 
transgenic models of neurodegenerative disease available to us at the initiation of our study in 
2002 our observations suggest that PrP does not have a major role in these models. Given the 
large number of mouse models of neurodegeneration, particularly AD, TP, and PD that have 
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been developed over the past seven years and the recent reports connecting PrP to β-amyloid 
generation and uptake, this question may be worth revisiting. A crucial experiment to test the 
relationship between PrP and AD will be to cross the PrP KO to a model mouse model of AD 
and assess memory loss and pathology. Although the results presented within this report are 
mainly negative, we report them because they represent a long and costly set of experiments 
that addresses a critical question to the field of neurodegenerative disease. 
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Figure legends 
 
Figure 1. PrP knockout mice are more susceptible to ischemia induced by transient middle 
cerebral artery occlusion-reperfusion. (A) Cerebral blood flow was measured in PrP+/+ and 
PrP-/- mice (n=8 PrP WT and n=7 PrP KO) undergoing MCAO to confirm that both groups had 
similar blockages of blood flow in the brain. (B) Behavioral testing of PrP KOs and controls. 
Higher clinical scores indicate more severe injury both 2 and 24 hours after injury (P<0.01, 
unpaired, two-tailed Student’s T test). (C) Infarct area measured across five brain regions (1 
anterior to 5 posterior shown in pane E). (D) Infarct volume in PrP+/+ and PrP-/- brains 
(P<0.001, two-tailed Student’s T test). (E) Representative sections from brain regions 1-5 are 
shown for PrP+/+ and PrP-/- brain sections from MCAO sections 1-5 are shown. 
 
Figure 2. PrP deletion in α-synuclein Tg mice. (A) Motor performance was assessed on an 
accelerating rotarod on a monthly basis (n=13-19 PrP+/+, n=9-17 PrP+/-, and n=16-21 PrP-/- 
PD Tg+ mice per time point; data shown as mean plus standard deviation). At 15 months of 
age PrP+/+ PD+ mice outperformed PrP-/- PD+ mice (*P<0.05, unpaired, two-tailed Student’s 
T test). (B) Survival analysis did not show a significant differences between PrP+/+ (n=28), 
PrP+/- (n=31), and PrP-/- (n=28) α-synuclein overexpression Tg mice (log rank test). (C-D) α-
synuclein staining of the ventral midbrain (substantia nigra). (E) a negative control from an α-
synuclein Tg- mouse is shown. Scale bar corresponds to 20µm. 
 
Figure 3. PrP deletion in P301L Tau Tg mice. (A) Motor performance was assessed on an 
accelerating rotarod; there were no significant differences (unpaired, two-tailed Student’s T 
test) among the experimental groups (n=9-14 PrP+/+ Tau Tg+, n=7-19 PrP+/- Tau Tg+, n=15-
26 PrP-/- Tau Tg+). (B) Survival analysis did not show a significant differences between 
PrP+/+ (n=17), PrP+/- (n=39), and PrP-/- (n=45) P301L Tau Tg mice (log rank test). (C-D) 
Representative image of neurofibrillary tangles detected by Tau immunohistochemistry. (E) A 
positive control of a human Alzheimer’s and (F) a negative control from a Tau Tg- mice is 
shown. 
 
Figure 4. PrP deletion in Huntington’s disease models. (A) Rotarod performance of PrP-/- HD 
Tg+ mice was improved over that of PrP+/+ HD Tg+ until the later points of disease (12-14 
weeks, *P<0.05, unpaired, two-tailed Student’s T test--individual comparisons of PrP+/+ to 
PrP-/- at each time point). (B) Survival of R6/2 HD mice was not altered by deletion of PrP 
(n=23 PrP+/+, n=37 PrP+/-, and n=20 PrP-/- R6/2 HD Tg+). (C) Clasping and (D) escaping 
were not altered by PrP deletion in HD Tg+ mice (HD Tg- mice all escape showed 100% 
escape at all time points and never clasp at any time point, data not shown). (E-F) 
Accumulation of nuclear aggregates of huntingtin in the cortex of PrP+/+ HD+ (E) and PrP-/- 
HD+ (F) and hippocampus of PrP+/+ HD+ (G) and PrP-/- HD+ (H). (I) Survival plot of N171-
82Q HD mice with PrP+/+ (n=5), PrP+/- (n=7), and PrP-/- (n=7); there were no significant 
differences in survival (log rank test). 
 
Figure 5. Overexpression of PrP in the R6/2 Huntington’s disease Tg. (A) There were no 
significant differences in rotarod performance of HD Tg+ PrP OE- and HD Tg+ PrP OE+ (n=22 
HD Tg+ PrP OE-, n=9 HD Tg+ PrP OE+; unpaired, two-tailed Student’s T test). (B) Survival of 
R6/2 HD mice was not altered by overexpression of PrP (same mice as used in survival study; 
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log rank test).  (C) Clasping and (D) escaping responses during tail suspension tests of HD 
Tg+ PrP OE- and HD Tg+ PrP OE+ (HD Tg- mice all showed 100% escaping responses at all 
time points tested and never clasped, data not shown). (E) Lateral distance traveled in the 
home cage over a 24 hour video recording (n=5-9 mice per group).  
 
 
 
 
 
 
Table I. Mouse strains used in this study 
 
Mouse model Common Name Genetic Alteration Original Reference 
Parkinson’s Disease D line human α-synuclein 
overexpression 
Masliah E., et al., 2000  
Tauopathy JNPL3 human P301L mutant 
Tau overexpression 
Lewis J., et al., 2000 
Huntington’s Disease R6/2, Bates fragment of human Htt 
gene with n=115-150 
glutamine expansion 
Mangiarini L., et al., 
1996  
Huntington’s Disease N171-82Q, 
Ross-Borchelt 
Fragment of human Htt 
with a n=82 glutamine 
expansion 
Schilling G., et al., 1999 
PrP knockout PrP KO Edinburgh Neomycin insertion into 
Prnp exon 
 Manson J., et al., 1994 
PrP overexpression Tga20 Mouse PrP 
overexpression 
Fischer M., et al., 1996 
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